Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Revenue growth above 20%Profit growth above 25%EBITDA margin compressionAuditor changed mid-yearResults View source PDF Explain this filing

MEDICO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹47.15

prior close

₹47.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.5%+1.9% vs market

Pharmaceuticals peers, median of 156sector-0.9%+1.3% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.4

15m

-0.4

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5-1.5+1.9-0.9+1.3

Next day

+3.1-2.2+5.3-1.5+4.6

+0.4-1.2+1.6-0.9+1.4

-0.3-0.9+0.6-0.5+0.2

-2.7-2.3-0.3-2.0-0.6

-2.5-2.5+0.0-2.2-0.2

-2.6-3.6+1.0-3.2+0.7

15d

-14.1-10.4-3.7-6.9-7.2

-13.0-11.3-1.7-8.6-4.4

-17.7-3.6-14.1-3.4-14.2

-9.3+3.9-13.2+0.9-10.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medico Remedies has reported its unaudited standalone results for Q3 FY26 and the nine months ended December 31, 2025. Revenue from operations for Q3 FY26 came in at Rs 5,868 lakhs, up roughly 49% YoY from Rs 3,949 lakhs in Q3 FY25, while net profit rose about 10% YoY to Rs 287 lakhs from Rs 262 lakhs. For the nine-month period, revenue grew about 36% YoY to Rs 14,957 lakhs and PAT grew about 26% YoY to Rs 726 lakhs, translating to an EPS of Rs 0.87. The company continues to be export-heavy, with about Rs 5,156 lakhs of Q3 sales coming from outside India versus Rs 690 lakhs domestically. There has also been a change in statutory auditor mid-year — from M/s V J Shah & Co to Shah Shroff & Associates — and the new auditor issued an unmodified limited review report.

Likely market impact

Strong top-line growth, especially from exports, is a positive signal, but Q3 profit growth of ~10% lagging revenue growth of ~49% suggests rising costs and margin pressure worth monitoring. The mid-year auditor change is a governance point shareholders should track.